Enzalutamide restores the testosterone effect on H19 expression in prostate cancer cells but not in exosomes

Ozgur, Emre; Gezer, Uğur

doi:10.5455/annalsmedres.2019.03.123

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diminished testosterone level supply is associated with the slow progression of cancer cells [ 16 ]. Therefore, luteinizing hormone releasing agonists (leuprolide, goserelin, triptorelin) are preferred to antagonize testosterone levels via preventing the testicles from synthesizing it [ 17 ]. Some anti-androgenic medications (bicalutamide, flutamide) are required to prevent the testosterone from reaching cancerous cells [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates

et al. 2020

View full text Add to dashboard Cite

The fabrication and development of nanomaterials for the treatment of prostate cancer have gained significant appraisal in recent years. Advancements in synthesis of organic and inorganic nanomaterials with charge, particle size, specified geometry, ligand attachment etc have resulted in greater biocompatibility and active targeting at cancer site. Despite all of the advances made over the years in discovering drugs, methods, and new biomarkers for cancer of the prostate (PCa), PCa remains one of the most troubling cancers among people. Early on, effective diagnosis is an essential part of treating prostate cancer. Prostate-specific antigen (PSA) or serum prostate-specific antigen is the best serum marker widely accessible for diagnosis of PCa. Numerous efforts have been made over the past decade to design new biosensor-based strategies for biomolecules detection and PSA miniaturization biomarkers. The growing nanotechnology is expected to have a significant effect in the immediate future on scientific research and healthcare. Nanotechnology is thus predicted to find a way to solve one of the most and long-standing problem, “early cancer detection”. For early diagnosis of PCa biomarkers, different nanoparticles with different approaches have been used. In this review, we provide a brief description of the latest achievements and advances in the use of nanoparticles for PCa biomarker diagnosis.

show abstract

Section: Introductionmentioning

confidence: 99%